-
Targeted drugs are constantly available, and breast cancer may become a manageable chronic disease
Time of Update: 2020-11-28
With the clinical application of CDK4/6 inhibitors in advanced breast cancer, the total survival of breast cancer patients has been greatly improved, said Professor Guo Shanxuan, deputy director of general surgery at the Ninth People's Hospital affiliated with Shanghai Jiaozhou University School of Medicine.
-
Cancer Cell overview article interpretation! How to develop a new generation of cancer therapy for CAR-T cell engineering modification?
Time of Update: 2020-11-28
CAR-T cell therapy has great potential in treating malignant hematosoma disease, but scientists still face great challenges in treating solid tumors, so they need to further engineer and adjust the base to successfully treat these incurable malignancies, and recent protein and cell engineering strategies have made great progress in enhancing the internal adaptability and anti-tumor function of T cells.
-
Nature sub-journal interpretation! How can cancer cells become more susceptible to death?
Time of Update: 2020-11-28
November 18, 2020 // -- Scientists from the University of Washington School of Medicine and others have revealed how cancer cells become more susceptible to death in a recent study published in the in
-
1 case of double genotype less protrusion cytoma histology, molecular, radiology and pathogenic characteristics
Time of Update: 2020-11-28
the pathology of the inner part of the tumor that was first removed was diagnosed as a low-level IDH1 mutant assoblastoma, and histological examination of the cut-off side after 7 months showed an immersive glioma consisting of two morphological patterns (Figure 2).
-
Cell interpretation! How does uncovering nerve tissue protect pancreatic cancer cells from hunger?
Time of Update: 2020-11-28
researcher Alec Kimmelman said the study provides more evidence that pancreatic cancer is an extraordinary metabolic scavenger, which may help maintain its deadly properties; the ability of nerve tissue to transport nutrients from the blood to the harsh micro-environment of pancreatic tumors is a very meaningful adaptation that could hopefully help researchers develop new therapeutic methods to intervene in this unique flexibility.
-
Br J Cancer: Comparison of the efficacy and safety of topological tycon and beloticon in a single therapy for relapsed small cell lung cancer
Time of Update: 2020-11-27
previous studies have shown that in a number of Phase 2 clinical trials, belotticon monotherapy has shown initial efficacy and good safety for relapsed SCLC.
, this randomized clinical trial aims to compare the efficacy and safety of topological tycon with beloticon as a monotherapy for relapsed small cell lung cancer.
-
T-cell activation and checkpoint suppression: triple immunotherapy to treat glioblastoma (GBM) 18-month survival rate of up to 50-70%!
Time of Update: 2020-11-27
total survival (OS) was 17.9 months in patients with non-methylated GBM, which was more favourable than in the historical control group; tested, most subjects showed a T-cell immune response to one or more tumor-related antigens encoded by INO-5401.
-
Get these 3 kinds of cancer, please be prepared! It's hard for the doctor to help you
Time of Update: 2020-11-27
People at high risk of pancreatic cancer, over 45 years of age, have chronic pancreatitis patients, early diabetes patients, if blood sugar continues to rise over a period of time to be vigilant; groups with family history; most people with gastric excision, generally after 20 years of higher risk of disease; long-term heavy drinking, smoking and exposure to chemical poisons should also be careful.
-
Treatment of meningioma
Time of Update: 2020-11-27
rock diagonal meningioma is adjacent to multiple groups of cranial nerves, cervical artery spongium sinus segments, substrate arteries, epidural arteries and brain back arteries junction, saddle nodule meningiomas and optic nerves and brain aneurysm complex, surgery should pay special attention to protect the complex and important structure closely linked to the tumor.
-
Tumor immunotherapy upgrade! AstraZenecom's Imfinzi new dosing program (1500mg once every 4 weeks) is approved by the FDA!
Time of Update: 2020-11-27
based on data from the Phase III CASPIAN trial, the Imfinzi Joint Standard Care (SoC) chemotherapy first-line treatment of broad-stage non-small cell lung cancer (ES-SCLC) was approved by the United States, the European Union, Japan and a number of other countries.
-
New drug for lymphoma! CD19 Target Antibody Association Drug (ADC) loncastuximab tesirine (Lonca) is under FDA priority review!
Time of Update: 2020-11-27
origin: ADC Therapeutics Announces FDA Accepts Biologics License application and Grants Priority Review for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diff Large B-cell Lymphoma
-
CA Cancer J Clin: For the first time, the system introduces the clinical application of circulating tumor DNA and its future direction
Time of Update: 2020-11-26
this review, the current and emerging applications of plasma ctDNA testing techniques in advanced solid tumor types are discussed, and the research methods that may be translated into clinical practice in the near future are highlighted.
-
It's just a little disgusting, why did you get a tumor? Be alert to this tumor, which, if found, may be late
Time of Update: 2020-11-26
Gastrointestinal mesothelioma, a tumor that sounds a little strange, is, in layman's terms, a potential malignant tumor produced by the upper extrinsic and muscle tissues of the stomach, which can occ
-
Cancer Cell: Breakthrough! Li Lin/Wu Tianqing/Li Wei collaborated to discover a new strategy for treating muscosa in the treatment room
Time of Update: 2020-11-26
Li Lin of the Center for Excellence and Innovation in Molecular Cell Science of the Chinese Academy of Sciences (Institute of Biochemistry and Cell Biology), Wu Tianqing of Yale University, and Li Wei of Fudan University Children's Hospital, worked together to publish a research paper entitled: Elevated CXorf67 Expression in PFA Epymomas Suppresses DNA Repair and Sensitizes to PARP Addors.
-
Nature Cancer: iNKT cell therapy "recruiter" - dual-specific antibody
Time of Update: 2020-11-26
Constant Natural Killer T cells (Invariant natural killer T cells, iNKT cells) are congenital CD1d restricted T cells that express constant T-cells (iTCR) and experience a unique differentiation proce
-
Br J Cancer:CX-5461, in combination with TOP1 inhibition, enhances the response to comotopous recombinant DNA damage in high-level slurry ovarian cancer and inhibits tumor growth
Time of Update: 2020-11-26
CX-5461 Joint Topology Inhibits HR Effective HGSC Cloning Survival and Tumor Growth Researchers found that cells that knocked out TOP1 (DNA Topology Isomerase 1) had significant inhibitory cell proliferation.
-
Science Advances: Chen Hong/Chen Gaojian's protrusion cells at Suzhou University become "sweeter" and greatly enhance anti-tumor effects
Time of Update: 2020-11-26
Therefore, the researchers believe that the DCs of the sugar polymer , a synthetic polygamose (pMAM) or polyglucose (pMAG) engineering modification that has an affinity for the sugar-sugar subjects, will be specifically attached to T cells through carbohydrate-coagulant binding.
-
GUT: Bacteria in cancer cells, Sun Yat-sen University Zhang Ge team revealed the tumor bacteria promote cancer metastasis mechanism
Time of Update: 2020-11-26
This research opens up a new field of infectious cell-specific exosomes in tumors, provides new insights into the molecular mechanism of carcinogenic bacterial-host interaction, and provides valuable ideas for clinical colorectal cancer treatment.
-
MSI-H/dMMR advanced solid tumors: how does each PD-1/PD-L1 perform?
Time of Update: 2020-11-26
On November 16, 2020, Synaptic Pharmaceuticals announced a new drug listing application (KN035) for a recombinant humanized PD-L1 monometric antibody Nvolly monoantigen injection (KN035) in a strategi
-
Take stock: A selection of Blod research on November 19, 2020
Time of Update: 2020-11-26
RunX1 and CBF beta-SMMHC common trans-activation abnormalities are consistent with leukemia https://doi.org/10.1182/blood.20200074716 chromosome inverted M4 subtype acute myeloid leukemia with acidoblastoid dystrophy (AML M4Eo) patients, which produces the CBFB-MYH11 fusion gene.
